Commitments and Contingencies |
3 Months Ended |
---|---|
Mar. 31, 2022 | |
Commitments and Contingencies | |
Commitments and Contingencies | H. Commitments and Contingencies Manufacturing Commitments As of March 31, 2022, the Company had noncancelable obligations under several agreements related to in-process and future manufacturing of antibody, drug substance, and cytotoxic agents required for supply of the Company’s product candidates totaling $18.3 million. Additionally, pursuant to commercial agreements for future production of antibody, our noncancelable commitments total $53.9 million at March 31, 2022. Litigation The Company is not a party to any material litigation. |